e-Drug3D

2028

SG3199

INN
LONCASTUXIMAB TESIRINE-LPYL

cas 1595275-71-0

CLASS

ANTINEOPLASTIC
TREATMENT OF B-CELL LYMPHOMA
ANTIBODY-DRUG CONJUGATE (ADC) TARGETING CD19
PYRROLOBENZODIAZEPINE (PBD) DIMER CYTOTOXIC ALKYLAT ING AGENT

ROUTE (list)

INJECTION

ATC code

L01FX22

PK parameters

VD 7.11 LITER

Target

TARGET DNA

DrugCentral

B-lymphocyte antigen CD19 UNIPROT P15391 CD19

Download SDF file

5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8,8'-[1,5-pentanediylbis(oxy)]bis[1,11a-dihydro-7-methoxy-2-methyl-, (11aS,11'aS)-

Formula:
C33H36N4O6

Calculated chemical properties:

MW 584.66
NB_atoms 43
XLogP 6.00
PSA 100.796
NB_HD 0
NB_HA 10
fsp3 0.39
Lipinski(0=no;1=yes) 0

FDA
NDA 761196 (label) INN (LONCASTUXIMAB TESIRINE-LPYL) ZYNLONTA (ADC THERAPEUTICS SA) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY